zolpidem has been researched along with Chronic Disease in 27 studies
Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.
zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this double-blind study was to compare, in a large primary care population of chronic insomniacs (> 4 weeks duration) the efficacy and safety of zolpidem 10 mg 5 nights/week and placebo 2 nights/week, to that of nightly zolpidem." | 9.10 | Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient study. ( Cluydts, R; Declerck, A; Estivill, SE; Hajak, G; Middleton, A; Sonka, K; Unden, M, 2002) |
| "In a parallel-group, placebo-controlled, polysomnographic study with randomization, the possible occurrence of rebound insomnia was evaluated in 24 patients suffering from moderate to severe chronic insomnia and receiving either triazolam 0." | 9.07 | Zolpidem and rebound insomnia--a double-blind, controlled polysomnographic study in chronic insomniac patients. ( Attali, P; de la Giclais, B; Monti, D; Monti, JM; Morselli, PL; Zipfel, A, 1994) |
| "A randomized, double-blind, placebo-controlled, parallel group multicenter trial was conducted to determine the effectiveness of 10 mg and 15 mg of zolpidem in the long-term (35 nights) treatment of chronic insomnia in 75 patients." | 9.07 | A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. ( Roth, T; Scharf, MB; Vogel, GW; Walsh, JK, 1994) |
| "The relative risk for hip fractures for suvorexant used in the model was based on data from pre-approval clinical trials." | 7.88 | Cost-effectiveness analysis of suvorexant for the treatment of Japanese elderly patients with chronic insomnia in a virtual cohort. ( Nakao, M; Nishimura, S, 2018) |
| "Changes in 24-h profiles of arterial pressure following treatment with zolpidem were studied in 12 patients with essential arterial hypertension and chronic sleep problems on enalapril." | 7.70 | [Combined use of zolpidem and enalapril in elderly patients with essential arterial hypertension and sleep problems]. ( Khapaev, BA; Ol'binskaia, LI, 2000) |
| " Adverse events were similar with almorexant and placebo." | 6.84 | Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference. ( Berkani, O; Black, J; Hajak, G; Hedner, J; Hmissi, A; Mangialaio, S; Pillar, G; Polo, O; Zammit, G, 2017) |
| "Alprazolam is a triazolobenzodiazepine derivative used as a tranquilizer." | 5.37 | Effects of Alprazolam, Zolpidem and Zopiclone, and of chronic inflammation on peripheral experimental algesia in Wistar rats. ( Antonescu, A; Bogdan, M; Dobjanschi, L; Moş, I; Mureşan, M; Muţiu, G; Zdrîncă, M, 2011) |
| " The aim of this double-blind study was to compare, in a large primary care population of chronic insomniacs (> 4 weeks duration) the efficacy and safety of zolpidem 10 mg 5 nights/week and placebo 2 nights/week, to that of nightly zolpidem." | 5.10 | Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient study. ( Cluydts, R; Declerck, A; Estivill, SE; Hajak, G; Middleton, A; Sonka, K; Unden, M, 2002) |
| "In a parallel-group, placebo-controlled, polysomnographic study with randomization, the possible occurrence of rebound insomnia was evaluated in 24 patients suffering from moderate to severe chronic insomnia and receiving either triazolam 0." | 5.07 | Zolpidem and rebound insomnia--a double-blind, controlled polysomnographic study in chronic insomniac patients. ( Attali, P; de la Giclais, B; Monti, D; Monti, JM; Morselli, PL; Zipfel, A, 1994) |
| "A randomized, double-blind, placebo-controlled, parallel group multicenter trial was conducted to determine the effectiveness of 10 mg and 15 mg of zolpidem in the long-term (35 nights) treatment of chronic insomnia in 75 patients." | 5.07 | A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. ( Roth, T; Scharf, MB; Vogel, GW; Walsh, JK, 1994) |
| "The relative risk for hip fractures for suvorexant used in the model was based on data from pre-approval clinical trials." | 3.88 | Cost-effectiveness analysis of suvorexant for the treatment of Japanese elderly patients with chronic insomnia in a virtual cohort. ( Nakao, M; Nishimura, S, 2018) |
| "Changes in 24-h profiles of arterial pressure following treatment with zolpidem were studied in 12 patients with essential arterial hypertension and chronic sleep problems on enalapril." | 3.70 | [Combined use of zolpidem and enalapril in elderly patients with essential arterial hypertension and sleep problems]. ( Khapaev, BA; Ol'binskaia, LI, 2000) |
| " Adverse events were similar with almorexant and placebo." | 2.84 | Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference. ( Berkani, O; Black, J; Hajak, G; Hedner, J; Hmissi, A; Mangialaio, S; Pillar, G; Polo, O; Zammit, G, 2017) |
| " Most frequent adverse events for zolpidem extended-release were headache, anxiety and somnolence." | 2.73 | Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. ( Erman, M; Krystal, AD; Roth, T; Soubrane, C; Zammit, GK, 2008) |
| "Zolpidem is a highly effective and safe medication for different type dyssomnia treatment that can be recommended for application in general clinical practice." | 2.70 | [Zolpidem (ivadal) treatment of sleep disorders]. ( Aleksandrovskiĭ, IuA; Androsova, VV, 2001) |
| "Diagnosis of insomnia is challenging because there can be many different causes and the clinical picture can be blurred by the presence of other psychiatric illnesses." | 2.40 | Pathophysiology and management of insomnia during depression. ( Kupfer, DJ, 1999) |
| "Zolpidem has been used with mixed effects in patients presenting with Prolonged Disorders of Consciousness (PDOC)." | 1.51 | An analysis of the effects of using Zolpidem and an innovative multimodal interdisciplinary team approach in prolonged disorders of consciousness (PDOC). ( Cronin, H; Delargy, M; Galligan, I; Gray, D; McCann, A; O'Connor, R; O'Toole, C, 2019) |
| "Zolpidem is an imidazopyridine nonbenzodiazepine hypnotic drug with a high affinity to the α1 subunit of the gamma amino butyric acid A receptor It is the first pharmacological option in the short-term management of sleep-onset insomnia." | 1.48 | Severe Chronic Abuse of Zolpidem in Refractory Insomnia. ( Bianco, G; Castelnovo, A; Chiaro, G; Maffei, P; Manconi, M, 2018) |
| "In total, 181 chronic insomnia patients were consecutively recruited." | 1.46 | Low serum 25-hydroxyvitamin D concentrations in chronic insomnia patients and the association with poor treatment outcome at 2months. ( Chen, H; He, J; Liu, Y; Luan, X; Qiu, H; Shen, H; Tu, X; Zhao, K; Zhu, Z, 2017) |
| "Alprazolam is a triazolobenzodiazepine derivative used as a tranquilizer." | 1.37 | Effects of Alprazolam, Zolpidem and Zopiclone, and of chronic inflammation on peripheral experimental algesia in Wistar rats. ( Antonescu, A; Bogdan, M; Dobjanschi, L; Moş, I; Mureşan, M; Muţiu, G; Zdrîncă, M, 2011) |
| " We show that the opioid Fentanyl, and its structurally similar sedative Zolpidem, can be embedded into metakaolin based geopolymer pellets to provide prolonged release dosage forms with mechanical strengths of the same order of magnitude as that of human teeth." | 1.36 | Mechanically strong geopolymers offer new possibilities in treatment of chronic pain. ( Bredenberg, S; Engqvist, H; Forsgren, J; Jämstorp, E; Strømme, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (18.52) | 18.2507 |
| 2000's | 14 (51.85) | 29.6817 |
| 2010's | 8 (29.63) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Black, J | 1 |
| Pillar, G | 1 |
| Hedner, J | 1 |
| Polo, O | 1 |
| Berkani, O | 1 |
| Mangialaio, S | 1 |
| Hmissi, A | 1 |
| Zammit, G | 1 |
| Hajak, G | 5 |
| Zhao, K | 1 |
| Luan, X | 1 |
| Liu, Y | 1 |
| Tu, X | 1 |
| Chen, H | 1 |
| Shen, H | 1 |
| Qiu, H | 1 |
| Zhu, Z | 1 |
| He, J | 1 |
| Nishimura, S | 1 |
| Nakao, M | 1 |
| Chiaro, G | 1 |
| Castelnovo, A | 1 |
| Bianco, G | 1 |
| Maffei, P | 1 |
| Manconi, M | 1 |
| Delargy, M | 1 |
| O'Connor, R | 1 |
| McCann, A | 1 |
| Galligan, I | 1 |
| Cronin, H | 1 |
| Gray, D | 1 |
| O'Toole, C | 1 |
| Buysse, DJ | 1 |
| Mets, MA | 1 |
| Volkerts, ER | 1 |
| Olivier, B | 1 |
| Verster, JC | 1 |
| Jämstorp, E | 1 |
| Forsgren, J | 1 |
| Bredenberg, S | 1 |
| Engqvist, H | 1 |
| Strømme, M | 1 |
| Zdrîncă, M | 2 |
| Muţiu, G | 1 |
| Bogdan, M | 1 |
| Dobjanschi, L | 1 |
| Antonescu, A | 2 |
| Moş, I | 1 |
| Mureşan, M | 1 |
| Walsh, JK | 2 |
| Cluydts, R | 2 |
| Heyde, K | 1 |
| De Volder, I | 1 |
| Veĭn, AM | 1 |
| Sudakov, KV | 1 |
| Levin, IaI | 1 |
| Iumatov, EA | 1 |
| Kovrov, GV | 1 |
| Strygin, KN | 1 |
| Posokhov, SI | 1 |
| Korabel'nikova, EA | 1 |
| Geisler, P | 1 |
| Krueger, TH | 1 |
| Kropp, S | 1 |
| Huber, TJ | 1 |
| Malloy, KM | 1 |
| Ketrick, J | 1 |
| Pribitkin, EA | 1 |
| Krystal, AD | 1 |
| Erman, M | 1 |
| Zammit, GK | 1 |
| Soubrane, C | 1 |
| Roth, T | 2 |
| Monti, JM | 1 |
| Attali, P | 1 |
| Monti, D | 1 |
| Zipfel, A | 1 |
| de la Giclais, B | 1 |
| Morselli, PL | 1 |
| Scharf, MB | 1 |
| Vogel, GW | 1 |
| Mangan, PS | 1 |
| Bertram, EH | 2 |
| Mehta, AK | 1 |
| Ticku, MK | 1 |
| Kupfer, DJ | 1 |
| Ol'binskaia, LI | 1 |
| Khapaev, BA | 1 |
| Aleksandrovskiĭ, IuA | 1 |
| Androsova, VV | 1 |
| Mtchedlishvili, Z | 1 |
| Kapur, J | 1 |
| Declerck, A | 1 |
| Estivill, SE | 1 |
| Middleton, A | 1 |
| Sonka, K | 1 |
| Unden, M | 1 |
| Bandelow, B | 1 |
| Zulley, J | 1 |
| Pittrow, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multi-center, Double-blind, Randomized, Placebo-controlled, Active Reference, Parallel-group Polysomnography Study to Assess the Efficacy and Safety of a 16-day Oral Administration of ACT-078573 in Adult Subjects With Chronic Primary Insomnia[NCT00608985] | Phase 3 | 709 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| "Evaluation of the Long-Term Efficacy and Safety of Zolpidem-MR 12.5 mg Compared to Placebo, When Both Are Administered Over a Long-Term Period as Needed, in Patients With Chronic Primary Insomnia"[NCT00425243] | Phase 3 | 1,025 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
LPS was defined as the time from the start of the PSG recording to the beginning of the first continuous 20 epochs (i.e., 10 minutes) scored as non-wake (i.e., either sleep stage 1 (S1), sleep stage 2 (S2), slow-wave sleep (SWS), or rapid eye movement sleep(REM)) as determined by PSG (NCT00608985)
Timeframe: From baseline to Day 1&2
| Intervention | minutes (Median) | ||
|---|---|---|---|
| Baseline | Day 1&2 | Change from baseline to day 1&2 | |
| Almorexant 100mg | 57.4 | 28.8 | -24.8 |
| Almorexant 200mg | 54.1 | 25.0 | -22.5 |
| Placebo | 57.3 | 37.5 | -15.8 |
| Zolpidem 10mg | 56.5 | 22.5 | -29.4 |
"WASO was defined as the time spent in epochs scored as wake after onset of persistent sleep as determined by polysomnography (PSG) until lights on.~For WASO assessed at the study center, the mean of the 2 PSG nights at each of Visits 3 and 4 was used for Day 1&2 and Day 15&16" (NCT00608985)
Timeframe: From baseline to Day 1&2
| Intervention | minutes (Median) | ||
|---|---|---|---|
| Baseline | Day 1&2 | Change from baseline to day 1&2 | |
| Almorexant 100mg | 86.6 | 54.5 | -29.0 |
| Almorexant 200mg | 92.3 | 46.4 | -40.4 |
| Placebo | 85.0 | 72.8 | -11.8 |
| Zolpidem 10mg | 76.5 | 54.6 | -17.9 |
LPS was defined as the time from the start of the PSG recording to the beginning of the first continuous 20 epochs (i.e., 10 minutes) scored as non-wake (i.e., either sleep stage 1 (S1), sleep stage 2 (S2), slow-wave sleep (SWS), or rapid eye movement sleep(REM)) as determined by PSG (NCT00608985)
Timeframe: From baseline to Day 15&16
| Intervention | minutes (Median) | ||
|---|---|---|---|
| Baseline | Day 15&16 | Change from baseline to day 15&16 | |
| Almorexant 100mg | 57.4 | 29.3 | -23.5 |
| Almorexant 200mg | 54.1 | 24.1 | -26.5 |
| Placebo | 57.3 | 30.0 | -20.0 |
| Zolpidem 10mg | 56.5 | 24.6 | -32.3 |
"WASO was defined as the time spent in epochs scored as wake after onset of persistent sleep as determined by polysomnography (PSG) until lights on.~For WASO assessed at the study center, the mean of the 2 PSG nights at each of Visits 3 and 4 was used for Day 1&2 and Day 15&16" (NCT00608985)
Timeframe: From baseline to Day 15&16
| Intervention | minutes (Median) | ||
|---|---|---|---|
| Baseline | Day 15&16 | Change from baseline to Day 15&16 | |
| Almorexant 100mg | 86.6 | 55.8 | -29.6 |
| Almorexant 200mg | 92.3 | 51.8 | -36.3 |
| Placebo | 85.0 | 65.0 | -18.3 |
| Zolpidem 10mg | 76.5 | 63.0 | -15.1 |
sLSO was the self-reported time to fall asleep as reported in the sleep diary (NCT00608985)
Timeframe: From baseline to Week 1&2
| Intervention | minutes (Median) | ||
|---|---|---|---|
| Baseline | Week 1&2 | Change from baseline to week 1&2 | |
| Almorexant 100mg | 55.0 | 36.5 | -16.2 |
| Almorexant 200mg | 53.3 | 34.5 | -16.2 |
| Placebo | 58.8 | 45.0 | -10.0 |
| Zolpidem 10mg | 50.5 | 33.3 | -17.2 |
sWASO was the self-reported time spent awake after sleep onset as reported in the sleep diary. For sWASO assessed at home, the mean of all available data collected between Visits 3 and 4 (i.e., after the second morning of Visit 3 and before the first evening of Visit 4) was used for Week 1&2 (NCT00608985)
Timeframe: From baseline to Week 1&2
| Intervention | minutes (Median) | ||
|---|---|---|---|
| Baseline | Week 1&2 | Change from baseline to week 1&2 | |
| Almorexant 100mg | 65.0 | 40.5 | -19.5 |
| Almorexant 200mg | 69.0 | 42.9 | -21.8 |
| Placebo | 64.0 | 52.9 | -14.1 |
| Zolpidem 10mg | 61.6 | 30.5 | -23.4 |
2 reviews available for zolpidem and Chronic Disease
| Article | Year |
|---|---|
Experience with zolpidem 'as needed' in primary care settings.
Topics: Chronic Disease; Clinical Trials as Topic; Drug Administration Schedule; Humans; Hypnotics and Sedat | 2004 |
Pathophysiology and management of insomnia during depression.
Topics: Anti-Anxiety Agents; Benzodiazepines; Brain; Chronic Disease; Depression; Female; Humans; Hypnotics | 1999 |
10 trials available for zolpidem and Chronic Disease
| Article | Year |
|---|---|
Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference.
Topics: Acetamides; Administration, Oral; Adolescent; Adult; Chronic Disease; Double-Blind Method; Female; H | 2017 |
Zolpidem "as needed" for the treatment of primary insomnia: a double-blind, placebo-controlled study.
Topics: Adult; Chronic Disease; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Male; Middle A | 2002 |
Polysomnographic findings during non-continuous administration of zolpidem.
Topics: Chronic Disease; Electroencephalography; Humans; Hypnotics and Sedatives; Polysomnography; Pyridines | 2002 |
Zolpidem "as needed" versus continuous administration: Pan-European study results.
Topics: Chronic Disease; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Age | 2002 |
Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study.
Topics: Adult; Analysis of Variance; Chronic Disease; Delayed-Action Preparations; Double-Blind Method; Drug | 2008 |
Zolpidem and rebound insomnia--a double-blind, controlled polysomnographic study in chronic insomniac patients.
Topics: Adult; Aged; Anxiety; Chronic Disease; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; | 1994 |
A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia.
Topics: Adult; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypnotics | 1994 |
[Zolpidem (ivadal) treatment of sleep disorders].
Topics: Adolescent; Adult; Aged; Chronic Disease; GABA Agonists; Humans; Hypnotics and Sedatives; Middle Age | 2001 |
Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient study.
Topics: Adolescent; Adult; Chronic Disease; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Ma | 2002 |
"As needed" pharmacotherapy combined with stimulus control treatment in chronic insomnia--assessment of a novel intervention strategy in a primary care setting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Behavior Therapy; Chronic Disease; Combined Modality The | 2002 |
15 other studies available for zolpidem and Chronic Disease
| Article | Year |
|---|---|
Low serum 25-hydroxyvitamin D concentrations in chronic insomnia patients and the association with poor treatment outcome at 2months.
Topics: Adult; Antidepressive Agents; Azabicyclo Compounds; Biomarkers; Case-Control Studies; Chronic Diseas | 2017 |
Cost-effectiveness analysis of suvorexant for the treatment of Japanese elderly patients with chronic insomnia in a virtual cohort.
Topics: Aged; Aged, 80 and over; Azepines; Chronic Disease; Computer Simulation; Cost-Benefit Analysis; Fema | 2018 |
Severe Chronic Abuse of Zolpidem in Refractory Insomnia.
Topics: Aged; Anticonvulsants; Chronic Disease; Clonazepam; Female; Hospitalization; Humans; Levetiracetam; | 2018 |
An analysis of the effects of using Zolpidem and an innovative multimodal interdisciplinary team approach in prolonged disorders of consciousness (PDOC).
Topics: Adult; Awareness; Chronic Disease; Consciousness Disorders; Female; Humans; Hypnotics and Sedatives; | 2019 |
Chronic insomnia.
Topics: Adult; Behavior Therapy; Chronic Disease; Combined Modality Therapy; Comorbidity; Depressive Disorde | 2008 |
Effect of hypnotic drugs on body balance and standing steadiness.
Topics: Acetamides; Adult; Aged; Alcohol Drinking; Azabicyclo Compounds; Benzodiazepines; Chronic Disease; D | 2010 |
Mechanically strong geopolymers offer new possibilities in treatment of chronic pain.
Topics: Analgesics, Opioid; Chronic Disease; Compressive Strength; Delayed-Action Preparations; Fentanyl; Hu | 2010 |
Effects of Alprazolam, Zolpidem and Zopiclone, and of chronic inflammation on peripheral experimental algesia in Wistar rats.
Topics: Alprazolam; Animals; Azabicyclo Compounds; Chronic Disease; Granuloma, Foreign-Body; Inflammation; M | 2011 |
[Specific features of the structure of sleep and personality under the conditions of chronic emotional stress and methods of improving the adaptive abilities of man].
Topics: Adaptation, Psychological; Adult; Chronic Disease; Delta Rhythm; Electroencephalography; Female; Hum | 2003 |
High-dose zolpidem dependence in a patient with chronic facial pain.
Topics: Adult; Chronic Disease; Facial Pain; Female; Humans; Pyridines; Substance Withdrawal Syndrome; Subst | 2005 |
Zolpidem tartrate use as contributory factor in sinus disease.
Topics: Chronic Disease; Female; Humans; Hypnotics and Sedatives; Middle Aged; Pyridines; Severity of Illnes | 2006 |
Ontogeny of altered synaptic function in a rat model of chronic temporal lobe epilepsy.
Topics: Animals; Chronic Disease; Electrophysiology; Epilepsy, Temporal Lobe; Hippocampus; Presynaptic Termi | 1998 |
Prevalence of the GABAA receptor assemblies containing alpha1-subunit in the rat cerebellum and cerebral cortex as determined by immunoprecipitation: lack of modulation by chronic ethanol administration.
Topics: Affinity Labels; Alcoholism; Animals; Azides; Benzodiazepines; Brain Chemistry; Central Nervous Syst | 1999 |
[Combined use of zolpidem and enalapril in elderly patients with essential arterial hypertension and sleep problems].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Drug Therapy, Combination; Enalapri | 2000 |
Diminished allopregnanolone enhancement of GABA(A) receptor currents in a rat model of chronic temporal lobe epilepsy.
Topics: Animals; Anticonvulsants; Chronic Disease; Diazepam; Electric Conductivity; Epilepsy, Temporal Lobe; | 2001 |